Overview

PF-04634817 Renal Impairment Study

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment. This study will investigate the effect of the drug in subjects with varying degrees of renal impairment. Pharmacokinetics, safety and toleration will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer